Evidence map›Paper›PMID 19825991›Full record

ArticleMolecular cancer research : MCR2009

PU.1 activation relieves GATA-1-mediated repression of Cebpa and Cbfb during leukemia differentiation.

Pavel Burda, Nikola Curik, Juraj Kokavec, Petra Basova, Dana Mikulenkova, Arthur I Skoultchi, Jiri Zavadil, Tomas Stopka

Abstract read
In one paragraph

Article in Molecular cancer research : MCR, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. PU.1 and Haematopoietic Cell Fate: Dosage Matters.International journal of cell biology · 2011
    Article
  13. Review
  14. Molecular mechanisms of ETS transcription factor-mediated tumorigenesis.Critical reviews in biochemistry and molecular biology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Pavel BurdaInstitute of Pathological Physiology and Center of Experimental Hematology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
Nikola Curik
Juraj Kokavec
Petra Basova
Dana Mikulenkova
Arthur I Skoultchi
Jiri Zavadil
Tomas Stopka
Charles University · CZAlbert Einstein College of Medicine · USNYU Langone Health · US

Funding

CBT and Modafinil for Cocaine AddictionR01DA016368 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MALCOLM, ROBERT JAMES · 2003 to 2009
$2.3M
Control of Erythroid Cell Division and DifferentiationR01HL078381 · NHLBI · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI SKOULTCHI, ARTHUR I · 2004 to 2008
$2.1M
CONTROL OF DIFFERENTIATION OF ERYTHROLEUKEMIC CELLSR01CA016368 · NCI · YESHIVA UNIVERSITY · PI SKOULTCHI, ARTHUR I · 1985 to 2003
$1.7M
Tailored Computerized Intervention for Behavior ChangeR15NR009021 · NINR · UNIVERSITY OF WISCONSIN MILWAUKEE · PI RYAN, POLLY · 2006 to 2006
$212k
NHLBI NIH HHS HL 78381NHLBI NIH HHS R01 HL078381NIDA NIH HHS R01 DA016368NINR NIH HHS R15 NR009021
6 · The paper itself

Abstract

Hematopoietic transcription factors GATA-1 and PU.1 bind each other on DNA to block transcriptional programs of undesired lineage during hematopoietic commitment. Murine erythroleukemia (MEL) cells that coexpress GATA-1 and PU.1 are blocked at the blast stage but respond to molecular removal (downregulation) of PU.1 or addition (upregulation) of GATA-1 by inducing terminal erythroid differentiation. To test whether GATA-1 blocks PU.1 in MEL cells, we have conditionally activated a transgenic PU.1 protein fused with the estrogen receptor ligand-binding domain (PUER), resulting in activation of a myeloid transcriptional program. Gene expression arrays identified components of the PU.1-dependent transcriptome negatively regulated by GATA-1 in MEL cells, including CCAAT/enhancer binding protein alpha (Cebpa) and core-binding factor, beta subunit (Cbfb), which encode two key hematopoietic transcription factors. Inhibition of GATA-1 by small interfering RNA resulted in derepression of PU.1 target genes. Chromatin immunoprecipitation and reporter assays identified PU.1 motif sequences near Cebpa and Cbfb that are co-occupied by PU.1 and GATA-1 in the leukemic blasts. Significant derepression of Cebpa and Cbfb is achieved in MEL cells by either activation of PU.1 or knockdown of GATA-1. Furthermore, transcriptional regulation of these loci by manipulating the levels of PU.1 and GATA-1 involves quantitative increases in a transcriptionally active chromatin mark: acetylation of histone H3K9. Collectively, we show that either activation of PU.1 or inhibition of GATA-1 efficiently reverses the transcriptional block imposed by GATA-1 and leads to the activation of a myeloid transcriptional program directed by PU.1.

Indexed as

CCAAT-Enhancer-Binding ProteinsCell DifferentiationCell Transformation, NeoplasticCore Binding Factor beta SubunitGATA1 Transcription FactorGene Expression Regulation, NeoplasticHeLa CellsHistonesHumansLeukemiaMyeloid CellsProto-Oncogene ProteinsProto-Oncogene Protein Spi-1Recombinant Fusion ProteinsRegulatory Elements, TranscriptionalRepressor ProteinsCBFB protein, humanCCAAT-Enhancer-Binding ProteinsCEBPA protein, humanCore Binding Factor beta SubunitGata1 protein, mouseGATA1 Transcription FactorHistonesProto-Oncogene ProteinsProto-Oncogene Protein Spi-1Recombinant Fusion ProteinsRepressor ProteinsRNA, Small InterferingTrans-Activators

Identifiers

PMID19825991
PMCPMC3193075
OpenAlexW2120231375

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.